Posters

Three years' results with a new phakic IOL in patients with myopia

Poster Details

First Author: A.Ağca TURKEY

Co Author(s):    D. Yasa   I. Cakir                 

Abstract Details

Purpose:

To report three years clinical experience with a foldable, hydrophilic acrylic, single piece, injectable, Phakic IOL.

Setting:

Prof. Dr. Nesat Belger Beyoglu Eye Research and Training Hospital, Istanbul, Turkey

Methods:

Retrospective analysis of 44 eyes of 22 patients who underwent phakic IOL implantation surgery from May 2015 to June 2016 was carried out. All the patients were implanted with hydrophilic acrylic phakic IOL (Eyecryl Phakic IOL, Biotech Vision Care, Ahmedabad, India). Keratometry, manifest refraction, endothelial cell count, uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) at various distance, and vault were obtained at 1, 3,6, 12, 24 and 36 months after surgery. Adverse Events/complications observed during and after surgery were also recorded.

Results:

The study included 44 eyes of 22 patients. Uncorrected Distance Visual Acuity (UCDVA), Uncorrected Intermediate Visual Acuity (UCIVA) and Uncorrected Near Visual Acuity (UCNVA) were 0.29 ± 0.25 logMAR, 0.29 ± 0.25 and 1.52 ± 0.84J respectively after 36 months of surgery. Refractive spherical equivalence and endothelial cell count were -12.75 ± 3.25 D and 2720.4 ± 337.78 cells/mm2 at pre-operative visit, -0.20 ± 0.84D and 2725.5 ± 887.10cells/mm² respectively at 36 months after surgery.

Conclusions:

Based on our three years postoperative experience, we have found Eyecryl Phakic IOL is safe and effective for treating mild and moderate myopia.

Financial Disclosure:

None